Interestingly, PTEN loss is associated with resistance to MEK inhibitors in a variety of cancers, and in fact may be a common mechanism for conferring resistance to other therapies such as PI3Kβ and BRAF inhibitors and immunotherapy [21, 22, 37–39]. The gene discussed is BRAF; the disease is cancer.